RSG
56
2
HIG
51
4
APH
58
5
UPS
53
3
LH
38
5
NTRS
44
5
MCK
59
3
DOW
47
3
COP
39
5
DHI
29
2
PWR
66
3
GLW
48
4
STT
64
5
SLG
38
3
INTU
57
3
D
35
2
LMT
44
5
O
30
10
RF
44
3
MDLZ
36
6
RSG
56
2
HIG
51
4
APH
58
5
UPS
53
3
LH
38
5
NTRS
44
5
MCK
59
3
DOW
47
3
COP
39
5
DHI
29
2
PWR
66
3
GLW
48
4
STT
64
5
SLG
38
3
INTU
57
3
D
35
2
LMT
44
5
O
30
10
RF
44
3
MDLZ
36
6
Financhill
Back

Innate Pharma SA 10K Form

Sell
46

IPHA
Innate Pharma SA

Last Price:
$2.05
Seasonality Move:
0.12%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive IPHA News And Ratings

See the #1 stock for the next 7 days that we like better than IPHA

IPHA Financial Statistics

Sales & Book Value

Annual Sales: $56.2M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $0.38
Price / Book: 5.4

Profitability

EPS (TTM): -0.45230
Net Income (TTM): $-36.7M
Gross Margin: $61.4M
Return on Equity: -72.79%
Return on Assets: -18.89%

Innate Pharma SA Earnings Forecast

Key Innate Pharma SA Financial Ratios

  • The Gross Profit Margin over the past 16 years for IPHA is 95.79%.
  • The Selling, General & Administrative Expenses for IPHA have been equal to 22.64% of Gross Profit Margin.
  • The Research & Development expenses have been 107.94% of Revenue.
  • The Interest Expense is -8.45% of Operating Income.
  • The Net Earning history of IPHA is -14.59% of Total Revenues.
  • Per Share Earnings over the last 19 years have been positive in 11 years.

Innate Pharma SA Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: IPHA
Website: innate-pharma.com

Debt

Debt-to-Equity Ratio: 1.23
Current Ratio: 2.92
Quick Ratio: 2.76

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

IPHA Technical Analysis vs Fundamental Analysis

Sell
46
Innate Pharma SA (IPHA) is a Sell

Is Innate Pharma SA a Buy or a Sell?

  • Innate Pharma SA stock is rated a Sell
    The current Innate Pharma SA [IPHA] share price is $2.06. The Score for IPHA is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.